Sign in
Taking people in United StatesPhase 1

CD19 CAR T cells after family donor transplant for leukemia and lymphoma

Tests CD19 CAR T cells after transplant in children with leukemia.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Registry title
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Status
Recruiting
Phase
Phase 1
People taking part
70 people, planned
Started
3 Oct 2026
Expected to end
Dec 2035
Type of study
Interventional
Treatments tested
  • Anti-Thymocyte Globulin (Rabbit)
  • Cyclophosphamide
  • Fludarabine
  • Thiotepa
  • Mesna
  • Melphalan
  • Filgrastim
  • CliniMACS System
Record updated
28 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people up to 21 years old with high-risk CD19-positive leukemia (ALL) who need a stem-cell transplant from a partly compatible family donor.

Age
Up to 21 years old.
Sex
All sexes can join.
Disease stage
High-risk CD19+ B-cell ALL in first or second remission, or any CD19+ B-cell ALL in third or later remission. Any past CNS leukemia must be treated and in CNS remission.
Earlier treatment
No earlier donor stem-cell transplant. The trial is for people with no HLA-identical sibling or 12/12 HLA-matched unrelated donor available in time.
Biomarker or test result
The leukemia must be CD19-positive.

Main reasons for not taking part

  • An HLA-identical sibling or 12/12 matched unrelated donor is available in time
  • Another active cancer besides the one being treated
  • A prior donor stem-cell transplant
  • Pregnancy or breastfeeding
  • A severe uncontrolled bacterial, fungal or viral infection

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Recipient
  • Age less than or equal to 21 years
  • High risk hematologic malignancy where allogeneic transplantation is the current standard of care. This includes (but is not limited to):; High risk CD19+ B cell ALL in CR1 or CR2; Any CD19+ B-cell ALL in CR3 or subsequent
  • If prior CNS leukemia, it must be treated and in CNS CR
  • Left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%
  • Creatinine clearance (CrCl) or glomerular filtration rate (GFR) ≥ 50 ml/min/1.73m2
  • Forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing
  • Karnofsky or Lansky (age dependent) performance score ≥ 50 (See APPENDIX A)
  • Bilirubin ≤ 3 times the upper limit of normal for age
  • Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age; Donor
  • At least single haplotype matched (≥ 4 of 8) family member
  • At least 18 years of age
  • HIV negative
  • If sexually active, agreement to use birth control until 2 weeks after completion of the mobilization and apheresis procedure
  • Regarding donation eligibility, is identified as either:; Completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR; Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271

Who cannot take part

  • Received a prior allogeneic HCT at any time
  • Any other active malignancy other than the one for which this HCT is indicated
  • Any severe current uncontrolled bacterial, fungal or viral infection; Donor
  • Pregnant, if female is of childbearing potential, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment
  • Pregnant, negative test must be confirmed by serum or urine pregnancy test within 14 days prior to enrollment if female
  • Recipient
  • Has a suitable HLA-identical sibling or suitable 12/12 (HLA-A, B, C, DRB1, DQB1, and DPB1) HLA-matched unrelated donor available in an appropriate time frame
  • If sexually active, agreement to use birth control until 6 months after T cell infusion
  • Breast feeding
  • If female, breast feeding

Where in United States

  • St. Jude Children's Research HospitalMemphis, United StatesContact: Swati Naik, MBBSTaking people

About the trial

What the trial wants to find out

The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.

Read full original descriptionShow less

Primary Objective:

- To assess the safety and feasibility of combining CD19-CAR(Mem) T cells after TCRαβ+/CD19 depleted haploidentical donor transplantation for pediatric patients with relapsed/refractory CD19+ B-cell malignancies.

Secondary Objectives:

* To estimate 1-year post-transplant overall survival, event-free survival, and GVHD-free relapse-free survival (GRFS). * To estimate cumulative incidence of engraftment, acute and chronic GVHD, and immune-related adverse events, including CRS and ICANS.

The group in the trial

  • HAPALL TreatmentTreatment being tested

    Patients receive a conditioning regimen that will comprise of ATG, Fludarabine, Cyclophosphamide. Melphalan and Thiotepa. Following the conditioning regimen, patients receive infusion of TCRαβ+/CD19 B cell depleted progenitor cell infusion on day 0. Then as early as day + 14 patients will receive the previously manufactured CD19-CAR(Mem) T cell product. Patients will then be monitored for safety and efficacy of the infused CAR T-cell product, Cells for infusion are prepared using the CliniMACS system.

    Treatment: Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna, Melphalan, Filgrastim, and CliniMACS System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
Plain-language title
CD19 CAR T cells after family donor transplant for leukemia and lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 August 2026